Clinical Trials Logo

Constriction, Pathologic clinical trials

View clinical trials related to Constriction, Pathologic.

Filter by:

NCT ID: NCT05885932 Recruiting - Ischemic Stroke Clinical Trials

Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis

VISTA
Start date: August 25, 2023
Phase: N/A
Study type: Interventional

Posterior circulation stroke accounts for 20% of all ischemic stroke. Approximately one quarter of posterior circulation strokes are due to stenosis in the vertebral artery and basilar artery. Two previous randomized controlled trials focusing on vertebral artery stenting, the Vertebral Artery Stenting Trial (VAST) and the Vertebral Artery Ischaemia Stenting Trial (VIST) were underpowered because they failed to reach target recruitment, and both the trials found no difference in risk of the primary outcome between the stenting group and medical group. The drug-eluting stenting versus medical therapy alone for patients with extracranial vertebral artery stenosis (VISTA) trial, is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit patients with 3 months stroke or TIA caused by 70-99% stenosis of extracranial vertebral artery (V1-2 segments). Only high-volume center with a proven track record will enroll patients. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus stenting. Primary outcome is a composite of any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year. The VISTA trial will be conducted in 30 sites in China and aims to have a sample size of 472 subjects (stenting, 236; medical treatment, 236). Recruitment is expected to be finished by Sep, 2025. Patients will be followed for 1 year at first stage. Long-term follow-ups till 3 years or longer is also preplanned. The first stage of the trial is scheduled to complete in 2027.

NCT ID: NCT05875675 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Effects of Pioglitazone in Calcific Aortic Valve Disease

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of pioglitazone compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.

NCT ID: NCT05864456 Recruiting - Clinical trials for Aortic Valve Stenosis

Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to evaluate the safety and efficacy of the Prizvalve Pro™ transcatheter aortic valve system in the treatment of patients with severe aortic stenosis who are at high risk of surgery or who are not suitable for surgery.

NCT ID: NCT05861648 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Folic Acid Supplementation in Calcific Aortic Valve Disease

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of folic acid compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.

NCT ID: NCT05857371 Recruiting - Urethral Stenosis Clinical Trials

Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy

SURF
Start date: March 13, 2024
Phase: Phase 2
Study type: Interventional

SURF is a randomised controlled, parallel group, single blind phase II study designed to assess the safety and potential efficacy of an innovative therapeutic strategy for urethral stenosis based on adjuvant injection of autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF) during endoscopic urethrotomy (standard care).

NCT ID: NCT05851209 Not yet recruiting - Aortic Stenosis Clinical Trials

Biomarkers and Mechanisms of Disease Progression and Outcome of Aortic Stenosis in Humans

Start date: July 1, 2023
Phase:
Study type: Observational

Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the development of hemodynamically relevant aortic valve stenosis in order to identify high-risk patients and to develop further therapeutic options.

NCT ID: NCT05850247 Not yet recruiting - CAROTID STENOSIS Clinical Trials

Plaque and Brain Inflammation in Symptomatic Carotid Stenosis: Role of the Ficolin-2

STATEMENT
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

Carotid artery stenosis is observed in about 3% of ≥ 60 years subjects and accounts for around 10-20% of all ischemic strokes. Beyond the degree of stenosis, plaque composition affects the risk of ischemic stroke. Identification of patients with vulnerable plaques at higher risk of stroke who might benefit from carotid revascularization is crucial. A growing body of evidence suggests that the lectin pathway of the complement system, and especially the ficolin-2, is involved in atherosclerosis. It has been hypothesized that circulating levels of ficolin-2 increase during chronic inflammatory conditions (i.e. growing atherosclerotic plaque) whereas they fall during sub-acute or acute inflammatory conditions (i.e. plaque rupture and acute ischemic stroke) because of consumption (binding to targets). Therefore, ficolin-2 has been proposed as a biomarker informing on the specific state of the plaque. However, in acute ischemic stroke due to carotid stenosis, both plaque rupture and stroke injury contribute to lectin pathway activation, thus affecting circulating levels of ficolin-2. Until now, the relative contribution of plaque and brain inflammation on circulating levels of ficolin-2 has not been documented. In the present study the investigators aim to assess the association between circulating levels of ficolin-2 and carotid and brain inflammation on [18F]DPA-714 positron emission tomography (PET)/MRI in patients with transient ischemic attack or acute ischemic stroke due to carotid stenosis. For that purpose, the investigators intend to include 30 patients with transient ischemic attack or acute ischemic stroke due to ≥ 50%. carotid stenosis. Each patient will have a measure of plasmatic level of ficolin-2 as well a [18F]DPA-714 PET/MRI to quantify the fixation of the radiotracer on carotid and brain.

NCT ID: NCT05848921 Not yet recruiting - Clinical trials for Carotid Artery Stenosis

Evaluation of Brain Health and Surgical Efficacy in Patients With Carotid Artery Stenosis

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to explore the relationship between the recovery of cerebrovascular morphology and cognitive function before and after surgical treatment in patients with carotid artery stenosis and their preoperative cardiac health status. And combined with preoperative cognitive status, serum markers, and cardiovascular health evaluation indicators, evaluate and predict the possibility of postoperative neurodegenerative diseases and the level of cerebrovascular health in patients.

NCT ID: NCT05847751 Not yet recruiting - Clinical trials for Severe Aortic Valve Stenosis

The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis

BSC07
Start date: January 2024
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to evaluate the ACURATE Neo2 in the Middle East population with severe, symptomatic aortic stenosis.

NCT ID: NCT05846893 Recruiting - Clinical trials for Coronary Artery Disease

Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease

REVERSE
Start date: September 7, 2023
Phase: N/A
Study type: Interventional

Prospective, randomised, open-label, international multicenter trial to evaluate the safety and efficacy of drug-coated balloon (DCB) treatment compared to drug-eluting stenting (DES) in patients with large coronary artery disease.